Structural basis and functional validation of the ABIMPROSYC platform
Science Behind the Platform
Our platform represents a fourth-generation nutritional immuno-architecture: formulas designed as functional layers, structured with GRAS-compatible elements, advanced vehicular systems, and synchronized with circadian and physiological rhythms. Unlike conventional supplements, it is not based on piling ingredients but on biostructural logic, operating through sequential schemes that align with specific biological pathways.
The scientific foundation of this approach is built on three pillars: validated functional density, regulatory compatibility with recognized nutritional-health categories, and ex vivo experimental confirmation in human-derived cellular systems.
Integrated Biofunctional Families
Each formula integrates macro-families of bioactive structures acting in synergy and in a non-therapeutic, regulatory-compliant manner. These families include redox-oriented systems, immunonutritional modulators, adaptogenic and neuromodulatory factors, bioenergetic and epigenetic cofactors, high-stability functional polyphenols, encapsulated synbiotic complexes, and regenerative peptide-based matrices. They are selected not for commercial notoriety but for their coherence with the physiological axes the platform seeks to support: immune surveillance, mitochondrial longevity, inflammatory resolution, and recovery after exertion.
.
Scientific Validation and Traceability
This platform does not emerge in isolation. It builds upon a robust scientific pipeline already validated in peer-reviewed journals and indexed in PubMed. Across this body of work, phospholipoprotein complexes have consistently demonstrated reproducible immune logic: coherent cytokine polarization, stability of proteomic fingerprints under diverse processing conditions, and the ability to modulate immune microenvironments without genetic or replicative components.
At the core lies the Structured Immunophenotypic Traceability Platform (STIP), a regulatory-aligned architecture capable of documenting immune consistency and enabling proportional validation without reliance on conventional clinical trial stages. Peer-reviewed studies — including Biology (2025) on functional stratification under STIP, Cancers (2025) on immune reprogramming, Biomedicines (2025) on vesicle fingerprint reproducibility, and IJMS (2025) on multi-stage monitoring protocols — collectively define the scientific backbone of this approach.
Originally conceived in advanced immunotherapy contexts, these principles now underpin the nutraceutical immunoceutical framework: auditable, biotech-grade, and structurally defensible. This marks the emergence of a new paradigm in wellness and performance — science-driven, evidence-based, and reproducible..
.
ADVANCED VEHICULATION TECHNOLOGY
ABIMPROSYC uses a triphasic administration system, adapted to physiological rhythms and specific biostructural requirements :
Soft liposomal capsule: transport of lipophilic active ingredients
(CoQ10, omega-3, glutathione, PQQ)- Dry vegetable functional capsule: enteric or sustained release of minerals, symbiotics and adaptogens
- Sublingual tablet: early release of melatonin, GABA, sulforaphane and other neuroactive ingredients
This system allows for differentiated release by route and time of day (AM/PM), optimizing the synergized intake of each functional group, without causing digestive interference., without
.
EX VIVO SUPPORT
The ABIMPROSYC platform has been subjected to ex vivo functional testing in human cell lines under controlled conditions, with the aim of documenting its biostructural activity without extrapolating clinical effects. In models such as THP-1, A375, and PANC1, the following were observed:
- Reduction of proinflammatory cytokines (IL-6 and TNF-α)
Increased IL-10, a marker associated with immunological resolution
- Decrease of intracellular ROS and preservation of cell viability
- Reduction of tumor viability in vitro without induction of uncontrolled necrosis
These results do not constitute therapeutic evidence, but they do support the formulas’ ability to modulate functional molecular environments, which strengthens their legitimacy as structured nutritional systems with professional applicability.
.
REGULATORY FRAMEWORK AND FUNCTIONAL SAFETY
All ingredients used in ABIMPROSYC comply with safety and eligibility regulations under:
- GRAS (21 CFR §170.30 – FDA, USA)
- Novel Food Regulation (Reg. EC 2015/2283 – European Union)
- Natural Health Products (Health Canada, NHPD)
They contain no pharmacological ingredients, do not induce active therapeutic mechanisms, and do not require a prescription. The formulation has been designed to avoid molecular overlap, minimize the risk of functional interactions, and ensure component traceability.
.
CONCEPTUAL SYNTHESIS
ABIMPROSYC is not defined by what it promises, but by what it structures. The science behind this platform doesn’t operate with empty claims or clinical assertions. Its validity is built on molecular coherence, pharmacotechnical architecture, and genuine compatibility with demanding metabolic environments , without invading the therapeutic domain.
.